利特昔替尼(ritlecitinib)在中国哪里能买到?

Purchase the generic version of ritlecitinib

ritlecitinib is developed and produced by Pfizer of the United States and has been launched in China on October 20, 2023 Yes, the current version of the generic version we know is the Lucius version, which is not on the market in mainland China and is not yet available in domestic hospital pharmacies. The current purchasing channels for the generic version are as follows:

1. Patients can purchase it in areas where it is already on the market, but they need to go to the local regular hospital pharmacy to purchase it with a prescription to avoid being deceived. This method requires high corresponding costs and heavy economic burden, and is not suitable for long-term medication.

2. Through the help of domestic professional overseas medical service institutions, the medicine can be mailed to your home. This method is more cost-effective and can save a lot of financial expenses. However, it is affected by many factors and is not fixed. The specific cost and acquisition process of the medicine need to be consulted by customer service staff.

The price of the generic version of ritlecitinib

Currently, we know that the Lucius (Hong Kong, China mail version) ritlecitinib specification is 50mg*28 capsules, and the price is about 1,470$ per box. The price is not fixed due to various factors.

Efficacy of ritlecitinib

A subgroup analysis of the ALLEGRO phase 2b/3 trial (NCT03732807) evaluated the efficacy and safety of the oral selective JAK3/TEC family dual kinase inhibitor ritlecitinib in patients aged 12 to 17 years with alopecia areata (AA).

Research Methods

In the ALLEGRO-2b/3 study, AA patients aged ≥12 years with ≥50% scalp alopecia received ritlecitinib 50 or 30 mg (± 4 weeks of 200 mg loading dose) or 10 mg or placebo once daily for 24 weeks. During a subsequent 24-week extension period, the ritlecitinib arm continued at its dose, while patients initially assigned to placebo were switched to a daily dose of 200/50 or 50 mg. Clinician- and patient-reported hair regrowth outcomes and safety were evaluated.

A total of 105 adolescents received randomized treatment. At Week 24, 17%-28% in the 30 mg and above treatment group had a Severity Alopecia Alopecia Tool (SALT) score ≤20 (≤20% hairless scalp), compared with 0% in the placebo group. At Week 48, 25%-50% of patients in the ritlecitinib treatment group (30 mg and above) had a SALT score ≤20.

At Week 24, 45% to 61% of adolescents in the ritlecitinib (30 mg and above) treatment group (compared with 10% to 22% in the placebo group) reported "moderate" or "large" improvement in AA, and 44% to 80% at Week 48.

Drug Safety

The most common symptoms among adolescents are headache, acne and nasopharyngitis. There were no reports of death, major adverse cardiovascular events, malignancy, pulmonary embolism, opportunistic infections, or herpes zoster infection.

Trial Conclusions

Ritlecitinib showed clinician-reported efficacy, patient-reported improvement, and acceptable safety at week 48 in adolescent patients with AA who had ≥50% scalp hair loss.

Recommended hot articles:

References

Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol. 2023 Nov-Dec;40(6):1003-1009. doi: 10.1111/pde.15378. Epub 2023 Jul 17. PMID: 37455588.